Patent 12234236

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

Original assignee

The original assignee, Ascletis Pharma China Co Ltd, is a biopharmaceutical company. Based on the patent title, "GLP-1R agonist and therapeutic method thereof," their primary line of business appears to be the research, development, and commercialization of therapeutic compounds, specifically GLP-1R agonists. While the patent describes compounds useful for treating GLP-1R-mediated diseases, the provided information does not explicitly state whether Ascletis Pharma China Co Ltd has shipped a product embodying the claims. The current status of Ascletis Pharma China Co Ltd is "Active".

Assignment timeline

Ascletis Pharma China Co Ltd is a biopharmaceutical company headquartered in Hangzhou, China, with operations focused primarily in mainland China. The company develops small-molecule and peptide therapeutics for metabolic diseases, infectious diseases, and other specialty indications. Ascletis Pharma has developed and marketed antiviral medicines, including danoprevir for hepatitis C, and has an authorized ritonavir tablet in China. They are actively involved in the development of GLP-1R agonists, including an oral small molecule GLP-1R agonist called ASC30, which has completed enrollment in a U.S. Phase II study for diabetes. The company's stock is listed on the Hong Kong Stock Exchange.

The USPTO Assignment Center (https://assignmentcenter.uspto.gov/) was searched for US patent 12234236. As of May 18, 2026, there are no recorded assignments for US Patent 12234236 in the USPTO Assignment Center. This indicates that the original assignee, Ascletis Pharma China Co Ltd, still owns the patent.

Timeline diagram

timeline
    title Ownership of US 12234236
    2024 : Application filed by Ascletis Pharma
    2025 : Issued to Ascletis Pharma

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. The patent remains with the original operating company, Ascletis Pharma China Co Ltd.
  2. Known asserter in the chain — not present. The current owner, Ascletis Pharma China Co Ltd, is a publicly traded biopharmaceutical company.
  3. Repeat correspondent across the chain — not present. There are no recorded assignments in the chain.
  4. Cascading transfers — not present. There are no recorded assignments.
  5. Pre-litigation transfer — not present. There are no recorded assignments. The current PGR challenge was filed while the patent is still owned by the original assignee.
  6. Bankruptcy fire-sale — not present. Ascletis Pharma China Co Ltd is an active, publicly traded company.
  7. Privateering — unclear. While Ascletis Pharma China Co Ltd is an operating company, without specific SEC filings or reports detailing assertion agreements, it's impossible to confirm or deny privateering.
  8. Defensive aggregator (anti-NPE) — not present. The patent is owned by an operating company, not a defensive aggregator.

Verdict

Insufficient data. There are no recorded assignments for US patent 12234236 in the USPTO Assignment Center. The patent remains with the original assignee, Ascletis Pharma China Co Ltd, which is an operating biopharmaceutical company. Therefore, there is no evidence of an NPE / patent-troll pattern in the ownership chain.

Generated 5/18/2026, 12:45:52 AM